{
    "clinical_study": {
        "@rank": "58734", 
        "arm_group": [
            {
                "arm_group_label": "ACTH", 
                "arm_group_type": "Experimental", 
                "description": "ACTH administered subcutaneously as a pulsed regimen of 3 consecutive days per month"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo subcutaneous injections administered on 3 consecutive days per month"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a phase II, randomized, double-blind, placebo-controlled, multi-center study to\n      evaluate the safety, tolerability, and efficacy of adrenocorticotropic hormone (ACTH, Acthar\n      gel) administered as a pulsed regimen consisting of injections on three consecutive days per\n      month in patients with progressive forms of Multiple Sclerosis (MS).  Patients will be\n      randomly assigned to either an ACTH arm or a placebo arm.  The main hypotheses are that 1)\n      pulsed ACTH will be safe and well-tolerated, and 2) pulsed ACTH will slow progression of\n      clinical and paraclinical measures of MS progression compared to placebo."
        }, 
        "brief_title": "ACTH in Progressive Forms of MS", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Secondary Progressive Multiple Sclerosis", 
            "Primary Progressive Multiple Sclerosis", 
            "Progressive Relapsing Multiple Sclerosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis", 
                "Multiple Sclerosis, Chronic Progressive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female patients with a confirmed diagnosis of MS by McDonald criteria\n\n          -  Age >/= 18 years\n\n          -  SPMS, PPMS, or PRMS phenotype, according to Lublin and Reingold criteria\n\n          -  EDSS 2.0 - 6.0, inclusive\n\n          -  Able to understand the consent process\n\n        Exclusion Criteria:\n\n          -  Known intolerance of ACTH or corticosteroids\n\n          -  Diabetes mellitus, defined as pre-existing diagnosis, fasting blood glucose > 125\n             mg/dl, or glycosylated hemoglobin >/= 6.5%\n\n          -  Osteoporosis, defined as pre-existing diagnosis or T-score on dual-energy x-ray\n             absorptiometry (DEXA) scan of </= -2.5.\n\n          -  Current serious medical condition which may interfere with subject's ability to\n             complete the study, or for which pulsed ACTH therapy is contraindicated or might\n             complicate current therapy (e.g., cancer, severe psychiatric illness, chronic\n             infections, autoimmune disorders)\n\n          -  Treatment with cytotoxic agents (including but not necessarily limited to\n             mitoxantrone, cyclophosphamide, alemtuzumab, or rituximab) within 3 years prior to\n             randomization\n\n          -  Treatment with non-cytotoxic immunosuppressive agents (including but not necessarily\n             limited to corticosteroids, ACTH, azathioprine, mycophenolate mofetil, methotrexate\n             or natalizumab) within 3 months prior to randomization\n\n          -  Treatment with FDA-approved first-line MS disease-modifying therapies (B-interferon,\n             glatiramer acetate, fingolimod, teriflunomide or dimethyl fumarate) will be\n             permitted, as long as treatment has been ongoing and stable for at least 3 months\n             prior to randomization\n\n          -  Treatment with dalfampridine or compounded 4-aminopyridine (4-AP) will be permitted\n             as long as treatment has been ongoing and stable for at least 3 months prior to\n             randomization\n\n          -  Stimulant medications for fatigue (such as methylphenidate, modafinil, armodafinil,\n             amantadine or dextroamphetamine) will be permitted, but subjects will be asked to not\n             take these medications on study visit days until all study procedures/assessments are\n             completed."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01950234", 
            "org_study_id": "ACTH-20712"
        }, 
        "intervention": [
            {
                "arm_group_label": "ACTH", 
                "description": "Acthar gel", 
                "intervention_name": "ACTH", 
                "intervention_type": "Drug", 
                "other_name": "Acthar gel"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Adrenocorticotropic Hormone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "October 23, 2013", 
        "location": {
            "contact": {
                "email": "cnru@umn.edu", 
                "last_name": "Susan Rolandelli, RN", 
                "phone": "612-624-7745"
            }, 
            "facility": {
                "address": {
                    "city": "Minneapolis", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55414"
                }, 
                "name": "Clinical Neuroscience Research Unit, University of Minnesota"
            }, 
            "investigator": {
                "last_name": "Adam F Carpenter, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Treatment of Progressive Forms of Multiple Sclerosis With Pulsed ACTH (Acthar Gel)", 
        "other_outcome": [
            {
                "description": "Brief Repeatable Battery of Neuropsychological Tests (BRB-N)", 
                "measure": "Slowed progression of sustained cognitive disability", 
                "safety_issue": "No", 
                "time_frame": "Month 36"
            }, 
            {
                "description": "Decline in retinal nerve fiber layer thickness as measured by optical coherence tomography (OCT)", 
                "measure": "Retinal nerve fiber layer thickness", 
                "safety_issue": "No", 
                "time_frame": "Month 36"
            }
        ], 
        "overall_contact": {
            "email": "cnru@umn.edu", 
            "last_name": "Susan Rolandelli, RN", 
            "phone": "612-624-7745"
        }, 
        "overall_official": {
            "affiliation": "University of Minnesota - Clinical and Translational Science Institute", 
            "last_name": "Adam F Carpenter, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Proportion of patients exhibiting a 20% worsening in T25FW at 36 months", 
            "safety_issue": "No", 
            "time_frame": "Month 36"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01950234"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Safety and tolerability will be assessed via safety lab tests, skin and edema assessments, DEXA scans, symptom questionnaires and adverse event assessments.", 
            "measure": "Safety and tolerability of ACTH", 
            "safety_issue": "Yes", 
            "time_frame": "Month 36"
        }, 
        "source": "University of Minnesota - Clinical and Translational Science Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "Questcor Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of Minnesota - Clinical and Translational Science Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}